Lucid Diagnostics (LUCD) Common Equity (2020 - 2026)

Lucid Diagnostics' Common Equity history runs 7 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• Quarterly Common Equity rose 174.39% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 174.39% YoY) and the FY2025 annual result came in at $10.9 million, up 102.86% from the prior year.
• Common Equity was $4.0 million for Q1 2026 at Lucid Diagnostics, down from $10.9 million in the prior quarter.
• Across five years, Common Equity topped out at $46.5 million in Q1 2022 and bottomed at -$5.4 million in Q1 2025.
• A 5-year average of $15.1 million and a median of $11.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity jumped 384.07% — and 2025, when it slumped 145.21%.
• Lucid Diagnostics' Common Equity stood at $23.0 million in 2022, then sank by 110.03% to -$2.3 million in 2023, then soared by 333.28% to $5.4 million in 2024, then jumped by 102.86% to $10.9 million in 2025, then slumped by 63.42% to $4.0 million in 2026.
• Business Quant data shows LUCD's Common Equity at $4.0 million in Q1 2026, $10.9 million in Q4 2025, and $25.8 million in Q3 2025.